ClinicalTrials.gg
RecruitingNCT03415828IDISUpdated Sep 29, 2025

Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain

An interventional study of Ethanol gel and Prednisolone acetate in Lumbar Discogenic Pain (Disorder), sponsored by Gelscom SAS. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Gelscom SAS · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2018; still recruiting 8 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 482 studies in Pain with a site in France — 75 open to participants now, 79 under way, 8 of them phase 3. Pain · France.

Planned enrollment
43rd of 369
230 · median 80
Started
2018
with 21 others
No phase
225 of 482
50 open now
Primary completion
2024-02
later than 4 of 78 live
Registered
255th of 482
by date

Among the 482 studies in Pain with a site in France, this one is the 43rd largest by planned enrollment of the 369 interventional ones that give a count, is one of 22 that started in 2018, is one of 225 with no phase, reaches primary completion later than 4 of the 78 other live ones, and was the 255th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

75 of the 482 studies in Pain with a site in France are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Pain with a site in France, or all of them as a file.
02

Study summary

DISCOGEL® is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017.

A clinical evaluation was performed by bibliographic route in 2016. Clinical data on more than 600 patients treated by DISCOGEL® were analyzed. These data should be confirmed by monitoring on the long term, with a large cohort of patients, over a two-year follow-up period.

As part of the post-CE surveillance, the manufacturer GELSCOM is responsible of this "Post-Market Clinical Follow-up" (PMCF) study in accordance with Directive 93/42/EEC and MEDDEV guide 2.12/2, to assess the efficacy and the long-term safety of DISCOGEL®.

The study is comparative. The results will evaluate the performance and safety of the CE-marked medical device used in "real life", in comparison with a steroid infiltration, used according to its indication and to the current standards. It will include economic data. Patients and evaluators will be blinded. Both DISCOGEL® and HYDROCORTANCYL 2,5 POUR CENT are authorized products used according to their intended use.

This is an interventional, prospective, national, multi-center, comparative, randomized, single-blind (patient and evaluator) post-market clinical study. The primary objective is to compare the short-term efficacy profile of DISCOGEL® versus intradiscal steroid.

03

Conditions studied

  • Lumbar Discogenic Pain (Disorder)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient 18 years of age or older;
  • 2-month pain to conservative treatment, non-surgical patients;
  • Chronic discogenic pain (1 or 2 lumbar discs) with concordant MR imaging;
  • Symptomatic for at least 8 weeks despite appropriate medical treatment;
  • Patient who agrees to participate in the study and who signed the form;
  • Patient with social protection.

Exclusion criteria

Exclusion Criteria:

  • Previous surgical treatment of the studied disc(s);
  • Patient with pure radicular pain;
  • Sick leave of more than 12 months secondary to the symptoms;
  • Patients who cannot read or write French;
  • History of cognitive-behavioral disorders that could interact with assessment by self-questionnaire;
  • Local or general infection, or suspicion of infection;
  • Severe coagulation disorders;
  • Other rheumatic inflammatory disease;
  • Undercurrent serious pathology with \< 2 years;
  • Female of childbearing age that are known to be pregnant during inclusion visit or wishing to become pregnant before treatment;
  • Subject who has forfeited their freedom by administrative or legal award, or is under guardianship or under limited judicial protection
  • Patient participating in another interventional clinical trial or testing an experimental drug within 30 days of inclusion in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Ethanol gel

    CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml

    Device: Ethanol gel

  • Active comparator
    Steroid infiltration

    Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml

    Drug: Prednisolone acetate

Interventions

  • DeviceEthanol gel

    Intradiscal injection of ethanol gel

    Also known as: DISCOGEL®

  • Intradiscal infiltration of steroids

    Also known as: HYDROCORTANCYL 2,5 POUR CENT

06

What researchers measure

Primary outcomes

  1. Short-term efficacy profile

    Compare the short-term efficacy profile of DISCOGEL® versus intradiscal steroid: percentage of patients with a pain relief defined by a Low Back Pain (LBP) intensity\<4 cm on a Local Verbal Rating Scale (0 = no pain to 10 = maximum imaginable pain)

    Time frame: Month 3

Secondary outcomes

  1. Long-term efficacy profile

    Compare the long-term efficacy profile of DISCOGEL® versus intradiscal steroid: Local Verbal Rating Scale: on back, bottom, thigh, leg, foot

    Time frame: Month 12

  2. Long-term efficacy profile

    Compare the long-term efficacy profile of DISCOGEL® versus intradiscal steroid: Local Verbal Rating Scale: on back, bottom, thigh, leg, foot

    Time frame: Month 24

  3. Short-term safety profile

    Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions

    Time frame: Month 3

  4. Long-term safety profile

    Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions

    Time frame: Month 12

  5. Long-term safety profile

    Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions

    Time frame: Month 24

  6. Questionnaire OSWESTRY

    Describe the rate of subjects improved 24 months after treatment: OSWESTRY scale

    Time frame: Month 24

  7. Questionnaire MacNab

    Subjective improvement 24 months after treatment: MacNab scale

    Time frame: Month 24

  8. Radiography

    Describe radiologic evolution of the lesions: radiography of the herniated disc

    Time frame: Month 3

  9. Radiography

    Describe radiologic evolution of the lesions: radiography of the herniated disc

    Time frame: Month 12

  10. Radiography

    Describe radiologic evolution of the lesions: radiography of the herniated disc

    Time frame: Month 24

  11. Magnetic Resonance Imaging

    Describe radiologic evolution of the lesions: MRI of the herniated disc

    Time frame: Month 3

  12. Procedures costs

    Compare the cost linked to the DISCOGEL® procedure and the cost linked to a steroid infiltration or surgery

    Time frame: Day 0

  13. Procedures durations

    Compare the duration of the treatment procedures between a DISCOGEL® injection and a steroid infiltration or surgery

    Time frame: Day 0

07

Study locations

3 of 5 sites recruiting
  • Hospital Pellegrin
    Bordeaux, France
    Recruiting
    • Mathieu de Sèze, Pr. · Contact
  • Hospital St-Dié-des-Vosges
    Saint-Dié, France
    Terminated

    Not enrolling at this site.

  • Hospital SUD La Reunion
    Saint-Pierre, France
    Recruiting
    • Romain Kohlmann, Dr. · Contact
  • Hospital St-Etienne
    Saint-Priest-en-Jarez, France
    Recruiting
    • Sylvain Grange, Dr. · Contact
  • Hospital Valence
    Valence, France
    Terminated

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Feb 2024, 69 months.

Of 99 industry-sponsored interventional studies with no phase under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 69 months is above that.

Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 30, 2018
StartActual
May 29, 2018
Primary completionActual
Feb 29, 2024
CompletionEst.
May 29, 2027
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03415828
Lead sponsor
Gelscom SAS
Collaborators
CEISO
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
May 29, 2018
Primary completion
Feb 29, 2024
Completion
May 29, 2027 (estimated)
Last update
Sep 29, 2025

Study contacts

Mathieu De Sèze, Dr
Contact
corinne.pallas@chu-bordeaux.fr
+335 56 79 55 16
Camélia Bentaleb
Contact
camelia.bentaleb@ceiso.fr
Mathieu de Sèze, Dr
study chair · CHU Bordeaux Pellegrin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion